How Analysts Feel About KemPharm, Inc. (KMPH) After Forming H&S Pattern?

July 14, 2018 - By James Guidry

KemPharm, Inc. (NASDAQ:KMPH) Logo

The stock of KemPharm, Inc. (KMPH) formed H&S with $4.94 target or 4.00 % below today’s $5.15 share price. The 9 months Head & Shoulders indicates high risk for the $81.16M company. It was reported on Jul, 14 by Faxor.com. If the $4.94 price target is reached, the company will be worth $3.25 million less.
Head-and-shoulders are one of the best chart patterns to trade. They work in bear and bull markets and according to many researchers have very low failure rate. Even thought they have high pullback rate, such patters usually provide good risk-reward entry opportunities. The percentage of stocks meeting price targets is 55%.

The stock decreased 6.36% or $0.35 during the last trading session, reaching $5.15. About 322,172 shares traded or 133.28% up from the average. KemPharm, Inc. (NASDAQ:KMPH) has risen 51.19% since July 14, 2017 and is uptrending. It has outperformed by 38.62% the S&P500.

Analysts await KemPharm, Inc. (NASDAQ:KMPH) to report earnings on August, 9. They expect $-0.98 EPS, down 122.73 % or $0.54 from last year’s $-0.44 per share. After $-1.11 actual EPS reported by KemPharm, Inc. for the previous quarter, Wall Street now forecasts -11.71 % EPS growth.

KemPharm, Inc. (NASDAQ:KMPH) Ratings Coverage

Among 5 analysts covering KemPharm (NASDAQ:KMPH), 5 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. KemPharm has $17 highest and $9.0 lowest target. $11.90’s average target is 131.07% above currents $5.15 stock price. KemPharm had 7 analyst reports since January 16, 2018 according to SRatingsIntel. The firm has “Buy” rating by Roth Capital given on Monday, April 2. The firm earned “Buy” rating on Tuesday, January 16 by RBC Capital Markets. The company was maintained on Monday, February 26 by Canaccord Genuity. Oppenheimer maintained it with “Buy” rating and $1300 target in Monday, April 2 report. Canaccord Genuity maintained KemPharm, Inc. (NASDAQ:KMPH) on Friday, February 23 with “Buy” rating. On Sunday, February 25 the stock rating was maintained by Oppenheimer with “Buy”.

More important recent KemPharm, Inc. (NASDAQ:KMPH) news were published by: Benzinga.com which released: “20 Stocks Moving In Monday’s Pre-Market Session” on July 09, 2018, also Benzinga.com published article titled: “41 Biggest Movers From Yesterday”, Seekingalpha.com published: “Evaluating KemPharm’s KP415, Part 3: KP415’s Potential” on July 03, 2018. More interesting news about KemPharm, Inc. (NASDAQ:KMPH) was released by: Benzinga.com and their article: “KemPharm’s ADHD Candidate Meets Efficacy, Safety Trial Endpoints” with publication date: July 09, 2018.

KemPharm, Inc., a clinical-stage specialty pharmaceutical company, discovers and develops new proprietary prodrugs in the United States. The company has market cap of $81.16 million. The Company’s lead product candidates are KP415, an extended release d-threo-methylphenidate product candidate for the treatment of ADHD; and KP201/IR, an IR formulation of KP201, a prodrug of hydrocodone and acetaminophen for the treatment of acute pain. It currently has negative earnings. The firm is also involved in developing KP511/ER, a prodrug of hydromorphone for the management of pain; KP511/IR for the short duration management of acute pain; KP606/IR, an IR formulation of KP606, a prodrug of oxycodone for the management of moderate to severe pain; KP746, a prodrug of oxymorphone for the management of moderate to severe pain; and KP303, a prodrug of quetiapine for the treatment of central nervous system disorders.

KemPharm, Inc. (NASDAQ:KMPH) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: